The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)

Pancreatic Exocrine Insufficiency Clinical Trial

— DETECTION  

Official title:

The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05980221
• Other study ID #: RRK6813
• Status: Recruiting
• Phase: N/A
• Start date: August 24, 2020
• Est. completion date: October 2024

Study information

• Verified date: August 2023
• Source: University Hospital Birmingham NHS Foundation Trust
• Contact: Sarah Powell-Brett, MBChB
• Phone: 07887754856
• Email: sarah.powell-brett1[@]nhs.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

DETECTION. The development of a metabolomic test to diagnose and quantify pancreatic exocrine insufficiency.

Description:

Pancreatic exocrine insufficiency (PEI) is prevalent and progressive among patients with pancreatic cancer, treatment with pancreatic enzyme replacement therapy (PERT) has been proven to reduce gastrointestinal symptoms, improve quality of life and survival and is therefore recommended in NICE guidelines. Despite this, most patients with PEI do not receive PERT. One cause for under treatment is lack of a well-tolerated and accurate diagnostic test that can provide quick results. The current, most widely used test, the faecal elastase stool test, has low accuracy, particularly after surgery, and results take several days. Furthermore, the test cannot help with dosing of PERT. Metabolomics can be used to quantify metabolites in blood. These metabolites are directly influenced by normal digestion and absorption of food, for example blood lipid levels are very different in the fed and fasted states. This program of work will give a standard meal to healthy controls and patients with PEI and screen their blood before and after a test meal. Differences in the metabolic profile will be used to develop a 'fingerprint' of PEI based upon one metabolite or a combination of metabolites. The ultimate goal is to develop a simple blood test that can be used outside of specialist centres that is acceptable to patients, can accurately diagnose PEI and can guide treatment with PERT. This body of work aims to investigate the metabolome of patients with PEI (of different causes), PEI will be defined in the different cohorts by a multimodel approach with the 13C MTGT as primary reference test and FE-1 and PEI-Q used as supporting tests. A test meal will be given to fasted participants alongside baseline blood samples and breath samples. Patients will then have blood and breath taken hourly for 6 hours. Blood samples will be spun and frozen for batch metabolomic analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria: (for main pancreatic cancer cohort)

• PDAC
• PEI (as defined by breath test)
• Tolerating oral diet Inclusion Criteria: (for CF cohort)
• CF
• PEI (as defined by breath test)
• Tolerating oral diet Inclusion Criteria: (for CP cohort)
• CP
• PEI (as defined by breath test)
• Tolerating oral diet

Exclusion Criteria (all arms):

• No other GI conditions
• For each arm no evidence of the other arm conditions
• For health controls, no history of CP, CF or pancreatic cancer
• No GI surgery (except pancreatic resection in the pancreatic cancer cohort)
• Unable to consent
• Unable to travel to UHB for testing
• Prognosis < 2months
• Performance status 2+

Related Conditions & MeSH terms

• Exocrine Pancreatic Insufficiency
• Pancreatic Exocrine Insufficiency

Intervention

Diagnostic Test:
• Metabolomics
Plasma samples taken for the investigation of the metabolome
• 13C MTGT
sequential breath samples taken for investigation of PEI (reference test)

Locations

Country	Name	City	State
United Kingdom	University Hospitals Birmingham NHS Foundation Trust	Birmingham

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Birmingham NHS Foundation Trust	Pancreatic Cancer UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolome	metabolomic fingerprint of patient with PEI in the fed and fasted state Bloods are taken in the fed and fasted state, after centrifugation, the plasma is then frozen at -80. Samples will then be analysed using untargeted liquid chromatography mass spectrometry, after which the raw data will be processed using the open-source software XCMS. The resultant metabolite features in the samples will be compared between healthy and diseased (PEI) cohorts to identify features specific to exocrine insufficiency.	1 year after study completion
Secondary	PEI status using 13CMTGT in comparison to the metabolome	breath test (13CMTGT). 13C labelled fatty test meal ingested, exhaled breath samples eveyr hour up to 6 hours, the cumulative percent dose of 13C recovered will then be used as a marker for PEI, diagnostic under 29%	1 year after study completion
Secondary	PEI status using FE-1 in comparison to the metabolome	FE-1. Faecal elastase, diagnostic <200	1 year after study completion
Secondary	PEI status using PEIQ in comparison to the metabolome	PEI-Q: Pancreatic exocrine insufficiency questionnaire (symptomatic assessment of PEI). >1.8 severe PEI, 1.4-1.8 moderate PEI, 0.6-1.4 mild PEI	1 year after study completion
Secondary	Response of the fed and fasted metabolome to PERT	Investigation of the metabolome in response to PERT low dose and high dose. The metabolomic profile indicative of PEI will then be assessed in a repeat cohort of patients that reattend twice on low dose and then high dose PERT. Bloods will be taken as for the main trial, in the fed and fasted state and the metabolomic profile (determined by the main cohort) will assessed using targeted liquid chromatography mass spectrometry to investigate whether it is altered by PERT (pancreatic exocrine replacement therapy)	1 year after study completion